Skip to main content

Table 3 Outcome measures – adjusted pairwise comparison of HCTZ monotherapy versus each fixed-dose combination therapy

From: Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy

 

HCTZ fixed-dose combination therapy

Outcome measures

ARB/HCTZ

ACEI/HCTZ

BB/HCTZ

Persistence (Odds Ratio, 95% CI)

0.369a

(0.356, 0.383)

0.380a

(0.368, 0.393)

0.382a

(0.370, 0.395)

Adherence (Odds Ratio, 95% CI)

0.457a

(0.440, 0.475)

0.495a

(0.478, 0.513)

0.398a

(0.385, 0.412)

PDC at end of follow-up period (Odds Ratio, 95% CI)

0.388a

(0.374, 0.403)

0.415a

(0.402, 0.429)

0.435a

(0.421, 0.449)

MPR (HCTZ vs. fixed-dose)

44.4 vs 61.0

Δ = -16.6b

44.6 vs 57.5

Δ = -12.9b

44.5 vs 61.5

Δ = -17.0b

  1. a Significant difference in outcome measures between pairwise comparison with HCTZ users at p < 0.05.
  2. b p < 0.0001